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Background and aims: Atherosclerosis is a chronic inﬂammatory disease of medium and large vessels and
is typically characterized by the predominant accumulation of low-density lipoprotein (LDL)-cholesterol
inside macrophages that reside in the vessel walls. Previous studies clearly demonstrated an association
speciﬁcally between the oxidized type of LDL (oxLDL) and atherosclerotic lesion formation. Further
observations revealed that these atherosclerotic lesions displayed enlarged, lipid-loaded lysosomes. By
increasing natural antibodies against oxLDL, pneumococcal vaccination has been shown to reduce
atherosclerosis in LDL receptor knockout (Ldlr/) mice. Relevantly, loss of the lysosomal membrane
protein Niemann-Pick Type C1 (NPC1) led to lysosomal accumulation of various lipids and promoted
atherosclerosis. Yet, the importance of lysosomal oxLDL accumulation inside macrophages, compared to
non-modiﬁed LDL, in atherosclerosis has never been established.
Methods: By transplanting NPC1 bone marrow into lethally irradiated Ldlr/ mice, a hematopoietic
mouse model for lysosomal cholesterol accumulation was created. Through injections with heat-
inactivated pneumococci, we aimed to demonstrate the speciﬁc contribution of lysosomal oxLDL accu-
mulation inside macrophages in atherosclerosis development.
Results: While there were no differences in plaque morphology, a reduction in plaque size and plaque
inﬂammation was found in immunized NPC1mut-transplanted mice, compared to non-immunized
NPC1mut-transplanted mice.
Conclusions: Lysosomal oxLDL accumulation within macrophages contributes to murine atherosclerosis.
Future intervention strategies should focus speciﬁcally on preventing oxLDL, unlike non-modiﬁed LDL,
from being internalized into lysosomes. Such an intervention can have an additive effect to current
existing treatments against atherosclerosis.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).L receptor knockout; NPC1,
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In 2013, cardiovascular disease (CVD) was a major cause of
mortality worldwide causing approximately 17 million deaths [1].
One of the major underlying pathologies of CVD is atherosclerosis.
Atherosclerosis is a chronic inﬂammatory disease of medium and
large vessels, which is characterized by the accumulation of both
lipid droplets and inﬂammatory cells in the vessel wall [2e4].
Macrophages are abundantly present in atherosclerotic lesions and
play an important role in the clearance of modiﬁed, oxidized low-s article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Primer sequences.
Gene Primer forward Primer reverse







M.L.J. Jeurissen et al. / Atherosclerosis 255 (2016) 59e6560density lipoproteins (oxLDL). These lipid-laden macrophages, also
known as foam cells, are one of the main drivers of atherosclerosis
development. Eventually, plaque rupture may occur, causing
thrombosis and/or stroke, which are hallmarks of CVD [5e7,49].
Over the years, an increasing amount of evidence has showed
the importance of immune activation in atherosclerotic lesions
[4,8]. Previously, natural antibodies targeted at oxLDL (EO6) were
shown to be abundantly present within atherosclerotic lesions
[9,10]. In line with these observations, our group and others
demonstrated that a pneumococcal-induced immune response
against the phosphorylcholine (PC) epitope, present on oxLDL,
leads to diminished atherosclerosis development and hepatic
inﬂammation [11,12]. Moreover, an elegant study by H€orkk€o et al.
clearly demonstrated that these antibodies speciﬁcally prevent
binding, uptake and degradation of oxLDL by macrophages [9].
These results demonstrate the importance of the uptake of oxLDL in
macrophages in the context of atherosclerosis development. In
general, after uptake by macrophages, cholesterol is initially
directed to the lysosomes for hydrolysis. Inside these lysosomes,
lysosomal enzymes mediate the hydrolysis of cholesteryl esters
into free cholesterol that can be transported out of the lysosomes
into the cytoplasm via Niemann-Pick Type C (NPC) proteins
[13e16]. As trafﬁcking of free cholesterol from the lysosome to the
cytoplasm is mainly regulated by NPC proteins, the dysregulation of
these NPC proteins plays an important role in atherosclerosis
development. Indeed, dysfunctional NPC1 leads to excessive accu-
mulation of various lipids, including both non-modiﬁed as well as
modiﬁed oxLDL, inside lysosomes [17,18]. Despite the fact that
several studies found that NPC1 plays an important role inFig. 1. Experimental set-up. Brieﬂy, lethally irradiated Ldlr/ mice were transplanted (-tp)
cholesterol accumulation speciﬁcally in the macrophages. To induce high levels of anti-oxL
(n ¼ 10), whereas control mice received PBS injections (n ¼ 12). After four weeks of immun
then were given immunizations every three weeks, until the end of the experiment.atherosclerosis, and that a number of in vitro studies clearly
demonstrated that it is speciﬁcally oxLDL that accumulates inside
lysosomes of macrophages [19,20], the speciﬁc contribution of
lysosomal oxLDL compared to non-modiﬁed LDL was neglected in
these studies and has never been established in vivo [21e23]. In the
current study, we aimed to demonstrate the contribution of lyso-
somal oxLDL accumulation to atherosclerosis, using a macrophage-
speciﬁc NPC1 mutant (NPC1mut) mouse model in combinationwith
pneumococcal immunization. In this study, we showed that
pneumococcal immunization of NPC1mut-transplanted (-tp) mice
led to a decrease in plaque lesion size, independently of cholesterol
levels, and a decline in plaque inﬂammation. Together, our results
indicate that lysosomal oxLDL accumulation inside macrophages
contributes to atherosclerosis.2. Materials and methods
2.1. Mice, bone marrow transplantation, immunization, and diet
All animals were housed under standard conditions and had
access to food and water ad libitum. All animal experiments were
approved by the committee for Animal Welfare of Maastricht
University and were performed according to the Dutch regulations.
The immunogen, Streptococcus pneumoniae (heat-inactivated
pneumococci, R36A strain, Birmingham, AL) was prepared as
described previously [24]. Niemann-Pick type C1m1N mutant
(NPC1mut) mice on a C57BL/6 background were a kind gift from
Prof. Dr. Lieberman from University of Michigan Medical School.
Ldlr/ mice were obtained from our in-house breeding. Bonewith bone marrow from mutant NPC1 (NPC1mut) mice. These mice develop lysosomal
DL antibodies, NPC1mut-tp mice were immunized with pneumococci every two weeks
ization, all mice were fed a high-fat, high-cholesterol diet (HFC) for twelve weeks and
Fig. 2. IgM auto-antibodies in plasma of NPC1mut-tp mice. Mice were immunized with Streptococcus pneumoniae strain R36A or treated with PBS (control). IgM auto-antibodies
targeted at oxLDL (EO6 and copper (Cu)-oxLDL) were measured in the plasma of immunized and non-immunized NPC1mut-tp mice. All data are represented as mean ± SEM. Data
are signiﬁcant at * p < 0.05, **p < 0.01, ***p < 0.001.
Table 2
Plasma lipid levels of NPC1mut-tp mice without immunization (control) or after
immunization with Streptococcus pneumoniae, strain R36A was determined at the





Cholesterol (mmol/l) 22.10 (±1.10) 20.81 (±0.78)
Triglycerides (mmol/l) 1.42 (±0.15) 1.42 (±0.13)
Free fatty acids (mmol/l) 0.96 (±0.05) 0.98 (±0.03)
M.L.J. Jeurissen et al. / Atherosclerosis 255 (2016) 59e65 61marrow transplantation and pneumococcal immunizations were
performed as described previously [11,25]. A detailed Materials andFig. 3. Histological analysis of plaque area in (non)-immunized NPC1mut-tp mice. (A) Re
area of the aortic root in (non)-immunized NPC1mut-tp mice. (C) Gene expression of Cd68
mean ± SEM. Data are considered to be signiﬁcant at * p < 0.05, **p < 0.01, ***p < 0.001.Methods section, concerning the methodology for the histological
analysis, immunohistochemistry, RNA isolation and qPCR, is avail-
able in the Supplemental Materials and Methods. The primer se-
quences can be found in Table 1. Groups were compared with the
two-way ANOVA for repeated measurements or by two-tailed un-
paired t-test using GraphPad Prism (Version 5.03). Outliers were
determined using the Grubbs' Test.3. Results
3.1. Plaque formation is reduced in NPC1mut-tp mice after
immunization, independently of plasma lipid levels
We used Ldlr/ mice, lethally irradiated and subsequentlypresentative pictures of the toluidine staining and (B) quantiﬁcation of the total plaque
in the aortic arch corrected for cyclophilin A expression. All data are represented as
Fig. 4. Quantiﬁcation of plaque morphology of (non)-immunized NPC1mut-tp mice in the aortic root. Representative pictures and quantiﬁcation of the MOMA-2 (A) and
collagen (B) staining in NPC1mut-tp mice immunized with R36A or control injections with PBS. Quantiﬁcation of necrosis (C) and apoptosis as demonstrated by a TUNEL staining (D)
in NPC1mut-tp mice immunized with R36A or control injections with PBS. All data are represented as mean ± SEM.
M.L.J. Jeurissen et al. / Atherosclerosis 255 (2016) 59e6562transplanted with bone marrow from NPC1mut mice, as a tool to
induce lysosomal cholesterol accumulation in hematopoietic cells.
To provoke an immune response to oxLDL, mice were immunized
with heat-inactivated Streptococcus pneumoniae (see Fig. 1 for the
experimental set-up). To conﬁrm previous studies that successfully
demonstrated elevated anti-oxLDL IgM titers after pneumococcal
immunization [11,12], we analyzed the IgM antibody titers in the
plasma of non-immunized and immunized NPC1mut-tp mice, at
different time points. Immunization with heat-inactivated pneu-
mococci led to a strong elevation of IgM autoantibodies directed
against oxLDL (EO6) compared to non-immunized mice (Fig. 2).
IgM antibodies directed against copper-oxLDL (Cu-oxLDL) were
also increased in immunized mice compared to control, at different
time points (Fig. 2). Moreover, the anti-oxLDL IgM responses were
sustained over time until the end of the experiment. Plasma lipid
levels were not signiﬁcantly different between immunized and
non-immunized mice (Table 2). Immunization of NPC1mut-tp mice
resulted in a trend (p ¼ 0.055) towards a reduced plaque area (17%)
in the aortic root (Fig. 3A and B). In the aortic arch, gene expression
of Cd68, a macrophage marker often used as surrogate marker for
plaque size [26,27], was signiﬁcantly reduced (43%) (Fig. 3C),
independently of plasma lipid levels.3.2. The inﬂammatory response is dampened in atherosclerotic
lesions in immunized NPC1mut-tp mice
To investigate whether immunization with heat-inactivated
pneumococci led to alterations in plaque morphology, we
analyzed monocyte/macrophage and collagen content, as well as
necrosis and apoptosis in the aortic root plaques of (non)-immu-
nized NPC1mut-tpmice. Immunohistological staining for monocyte/
macrophage content revealed no signiﬁcant differences between
immunized and non-immunized mice (Fig. 4A). Similarly, collagen
content assessed by Sirius Red staining, as well as the amount of
necrosis and apoptosis, was not different between the two groups
(Fig. 4BeD). To examine whether immunization with heat-
inactivated pneumococci led to reduced plaque inﬂammation, in-
ﬂammatory gene expression levels were determined in the aortic
arch of NPC1mut-tp mice. Gene expression levels of the inﬂamma-
tory markers tumor necrosis factor-alpha (Tnfa), CeC chemokine
receptor type 2 (Ccr2) and integrin Alpha M (Itgam) showed a trend
towards reduced expression in immunized NPC1mut-tp mice but
was not considered signiﬁcant when compared to control
(Fig. 5AeC). Inﬂammasome activation, triggered by oxLDL crystals,
is involved in atherosclerosis development and can be measured by
one of its downstream targets, namely caspase-1 that in turn ac-
tivates interleukin-18 (IL-18) [27]. Caspase-1 gene expression was
Fig. 5. Quantiﬁcation of plaque inﬂammation in (non)-immunized NPC1mut-tp mice in the aortic arch. (AeE) Relative gene expression of Tnfa, Caspase-1, Ccr2, Itgam and Il-18
in NPC1mut-tp mice immunized with R36A or control injections with PBS. All data are represented as mean ± SEM. Data are signiﬁcant at * p < 0.05, **p < 0.01, ***p < 0.001.
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mice, whereas no changes in gene expression of Il-18 were
observed (Fig. 5D and E). Despite a clear reduction in Caspase-1
mRNA expression in the aortic arch, we did not observe any
changes in caspase-1 activity in the aortic root between immunized
and non-immunized NPC1mut-tp mice, most likely due to the
presence of large necrotic areas (Supplementary Fig. 1).
To expand our analyses of inﬂammation, we performed addi-
tional staining for macrophages (MAC-1), neutrophils (NIMP) and
T-cells (CD3þ). No differences were observed in the number of
MAC-1 positive cells between the two experimental groups and
showed that MAC-1 is mainly expressed on foam cells, which is in
line with our staining of MOMA, which is also expressed on mac-
rophages (Supplementary Fig. 2). Next, immunohistological stain-
ing for neutrophils and T-cells was performed on frozen tissue
sections of the aortic root of immunized and non-immunized
NPC1mut-tp mice. No differences in the amount of neutrophils be-
tween immunized and non-immunized NPC1mut-tp mice were
observed. In contrast, a signiﬁcant increase in the amount of T-cells
was observed in immunized NPC1mut-tp mice (Supplementary
Fig. 3). However, it is important to note that increased T-cell
amounts could constitute a reaction to dampen inﬂammasome
activation [28], which could explain these ﬁndings.4. Discussion
Our results demonstrate that pneumococcal immunization can
modulate atherogenesis in hematopoietic NPC1-deﬁcient Ldlr/
mice. While previous studies showed that pneumococcal immu-
nization led to reduced lysosomal cholesterol accumulation [12],
the current ﬁndings demonstrate the speciﬁc importance of oxLDL
within lysosomes in atherosclerosis development.The aim of this study was to demonstrate the contribution of
lysosomal oxLDL accumulation, rather than non-modiﬁed LDL, to
atherosclerosis, by exclusively preventing the macrophage-
mediated uptake and subsequent storage of oxLDL in NPC1mut-tp
mice. We show that upon induction of anti-oxLDL antibodies,
atherosclerosis development is reduced in NPC1mut-tp mice
compared to non-immunized mice. In vitro, it has been shown that,
unlike LDL, oxLDL is retained in the lysosomes and is resistant to
efﬂux into the cytoplasm [29e31]. Stimulation of murine macro-
phages with oxLDL led to increased production of TNF and IL-6 in
response to LPS stimuli [32]. Studies also demonstrated that oxLDL
uptake by macrophages led to a release of pro-inﬂammatory cy-
tokines via reactive oxidant species (ROS)-dependent inﬂamma-
some activation, thereby promoting foam cell formation [33,34].
These in vitro ﬁndings clearly demonstrated the major contribution
of oxLDL to foam cell formation and inﬂammation, thereby inﬂu-
encing atherosclerosis development. In line with this observation,
despite a similar relative monocyte/macrophage content, gene
expression analysis of the aortic arch revealed that caspase-1
expression was signiﬁcantly reduced in immunized NPC1mut-tp
mice in the current study. Indeed, numerous studies have shown
that caspase-1 plays an important role in atherosclerosis [27,35,36].
In previous studies, we already demonstrated that pneumococcal
immunization resulted in reduced lysosomal cholesterol accumu-
lation and cholesterol crystal formation [12]. In line with these
ﬁndings, others observed that cholesterol crystal-induced inﬂam-
masome activation contributes to the development of atheroscle-
rosis via caspase-1-mediated activation [37]. These observations
indicate that blocking oxLDL uptake in macrophages of immunized
NPC1mut-tp mice results in a reduced caspase-1-mediated inﬂam-
matory response.
Uptake of oxLDL is mainly facilitated by CD36 and macrophage
M.L.J. Jeurissen et al. / Atherosclerosis 255 (2016) 59e6564scavenger receptor 1 (MSR1) and contributes to foam cell formation
[38]. Previous research of our group demonstrated that while there
was a clear reduction in inﬂammation, foam cell formation was
unaltered in Cd36/-tp, Msr1/-tp and Cd36//Msr1/-tp mice
compared toWt-tp mice [25,39]. Further detailed analysis revealed
that speciﬁcally oxLDL is internalized by macrophages, and this has
been shown to be associated with lysosomal cholesterol accumu-
lation and increased inﬂammation. Prevention of oxLDL uptake led
to a reduction of lysosomal cholesterol accumulation and a
decrease in inﬂammation in vivo [39,40]. Overall, these data indi-
cate that it is not the total amount of cellular cholesterol, but rather
the speciﬁc accumulation of lysosomal oxLDL that contributes to
atherosclerosis development and inﬂammation.
Although lipid-lowering agents are the primary treatment for
atherosclerosis and other CVDs, the residual risk for a cardiovas-
cular event remains present in these patients [41e43]. As not total
cholesterol, but rather the uptake of oxLDL is contributing to the
development of atherosclerosis, lowering LDL alone may not be
efﬁcient. In the past, numerous in vitro and in vivo studies have
shown that anti-oxidants could be beneﬁcial in reducing athero-
sclerotic lesions [44]. Surprisingly, despite some observational
studies that showed a correlation between anti-oxidants and
atherosclerosis, primary and secondary intervention clinical ran-
domized studies failed in humans [44]. The fact that cholesterol can
undergo oxidation within lysosomes could be important to explain
why these studies failed [45] and why we have observed only a
moderate reduction in atherosclerotic lesion size within this study.
Besides oxLDL, other cholesterol products such as aggregated LDL,
sphingomyelin and cholesteryl ester-rich lipid dispersions can also
accumulate inside lysosomes [29,46,47]. This could also explain the
moderate reduction in plaque size in the current study when
compared to previous ﬁndings by Binder et al. who performed
similar pneumococcal immunizations in hyperlipidemic mice
without an NPC1 mutation [11]. Taking into account the negligible
plasma oxLDL concentrations relative to LDL [48], the reduction in
plaque size and inﬂammation exceeded our expectations and un-
derlines the importance of oxLDL in atherosclerosis development.
Future intervention strategies should focus speciﬁcally on pre-
venting oxLDL, rather than non-modiﬁed LDL, from being inter-
nalized into lysosomes. Such an intervention can have an additive
effect to current existing treatments against atherosclerosis.Conﬂict of interest
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